Participate in Research

TRK Fusion Cancer Study
Protocol: SITE00000072
Full Title
ON-TRK: PrOspective Non-interventional study in patients with locally advanced or metastatic TRK fusion cancer treated with larotrectinib
This study enrolls people with TRK fusion cancer. The purpose of this study is to learn more about the effectiveness of the drug VITRAKVI (generic name: larotrectinib) for TRK fusion cancer that has spread from the place where it started to other places in the body. TRK fusion cancer is a term used to describe a variety of common and rare cancers that are caused by a change to the NTRK (Neurotrophic Tyrosine Kinase) gene called a fusion. VITRAKVI is an approved drug that blocks the action of the NTRK gene fusion.

This is an observational study, which means you will continue with the treatment your doctor has recommended and we will collect some data about your health while you are in treatment and afterwards for about 2-5 years. You will have phone calls with the study team once in a while to help us learn how you have been doing medically. Study takes place at Kaleida Health facilities.
Compensation: Yes
Compensation may include cash, checks, gift cards, debit cards, or incentives like gift baskets, technology items, or merchandise.
Adults 18+
Patients with TRK fusion cancer (locally advanced or metastatic solid tumor harboring an NTRK gene fusion).
Your physician has decided to treat you with larotrectinib.
Age Group: Both Adults and Children
Principal Investigator: ROBERTO PILI Open Study
Asif Abidi
Want to Learn More?

Let us know how the study team can reach you. If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email and someone will assist you.

Your information will be shared only with the research study team for recruitment purposes and designated CTSI personnel for project quality assurance and will remain confidential. Your information will be stored indefinitely. Should you no longer want this information to be provided in the aforementioned ways, please contact